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ABSTRACT Isavuconazole, the active moiety of the water-soluble prodrug isavu-
conazonium sulfate, is a triazole antifungal agent for the treatment of invasive fun-
gal infections. The purpose of this analysis was to characterize the isavuconazole
exposure-response relationship for measures of efﬁcacy and safety in patients with
invasive aspergillosis and infections by other ﬁlamentous fungi from the SECURE
clinical trial. Two hundred thirty-one patients who received the clinical dosing regi-
men and had exposure parameters were included in the analysis. The primary drug
exposure parameters included were predicted trough steady-state plasma concentra-
tions, predicted trough concentrations after 7 and 14 days of drug administration,
and area under the curve estimated at steady state (AUCss). The exposure pa-
rameters were analyzed against efﬁcacy endpoints that included all-cause mortal-
ity through day 42 in the intent-to-treat (ITT) and modiﬁed ITT populations, data re-
view committee (DRC)-adjudicated overall response at end of treatment (EOT),
and DRC-adjudicated clinical response at EOT. The safety endpoints analyzed
were elevated or abnormal alanine aminotransferase, increased aspartate amino-
transferase, and a combination of the two. The endpoints were analyzed using lo-
gistic regression models. No statistically signiﬁcant relationship (P  0.05) was found
between isavuconazole exposure and either efﬁcacy or safety endpoints. The lack of
association between exposure and efﬁcacy indicates that the isavuconazole expo-
sures achieved by clinical dosing were appropriate for treating the infecting organ-
isms in the SECURE study and that increases in alanine or aspartate aminotransfer-
ase were not related to increase in exposures. Without a clear relationship, there is
no current clinical evidence for recommending routine therapeutic drug monitoring
for isavuconazole.
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The morbidity and mortality from invasive fungal diseases remain substantial (1).Triazole antifungal agents are ﬁrst-line agents for the prevention and treatment of
these infections. Voriconazole is recommended as primary treatment for invasive
aspergillosis (IA). Posaconazole is primarily indicated as salvage therapy for patients
with IA and prophylaxis for patients with neutropenia and hematopoietic stem cell
transplant recipients (2). Isavuconazole administered as the prodrug isavuconazonium
sulfate is a novel broad-spectrum triazole antifungal agent. Isavuconazonium sulfate
has been approved by the U.S. Food and Drug Administration for the treatment of
adults with IA and invasive mucormycosis (3) and by the European Medicines Agency
for the treatment of adults with IA and those with mucormycosis for whom ampho-
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tericin B is not appropriate (4). In the SECURE clinical trial (ClinicalTrials.gov registration
no. NCT00412893) (Fig. 1), isavuconazole was demonstrated to be noninferior to
voriconazole for the primary treatment of invasive mold disease caused by Aspergillus
and other ﬁlamentous fungi, as determined using all-cause mortality through day 42 as
the primary endpoint (19% versus 20%, respectively) (5). Overall response and clinical
response rates were similar for isavuconazole and voriconazole (50% versus 47% and
62% versus 60%, respectively), and the isavuconazole group had signiﬁcantly lower
rates of hepatobiliary disorders (9% versus 16%), eye disorders (15% versus 27%), skin
or subcutaneous tissue disorders (33% versus 42%), and drug-related adverse events
(42% versus 60%).
A deep understanding of the relationship between drug exposure and response is
required to establish clinically useful threshold values for drug exposure for both
clinical outcomes and adverse events. Exposure-response relationships for efﬁcacy are
well established for other currently approved triazoles, such as itraconazole, posacona-
zole, and voriconazole, which has led to target drug concentrations that are necessary
to maintain drug levels within safe and effective ranges (6–10). Exposure-response
relationships for safety are also well established for itraconazole and voriconazole
(8, 11). Thus, an important question remains as to whether these relationships are
also evident for isavuconazole. Establishing clinically relevant exposure-response
and exposure-safety relationships will inform guidelines with respect to the potential
need for therapeutic drug monitoring (TDM).
In the SECURE trial, plasma isavuconazole concentrations were available for the
majority of patients who were enrolled in the isavuconazole arm. Therefore, this post
hoc analysis was conducted to evaluate the exposure-response relationships in terms of
efﬁcacy and safety for isavuconazole using those patient data. Logistic regression
modeling was used to explore the potential relationships between various measures of
isavuconazole exposure and both clinical outcomes and adverse events.
RESULTS
Data for analysis. Two hundred thirty-one patients from a previously developed
population pharmacokinetic (PPK) model provided exposure parameters (12) used in
the exposure-response analysis for both clinical outcomes and safety. One hundred
twenty-nine patients qualiﬁed for the modiﬁed intent-to-treat (mITT) population based
on data review committee (DRC)-adjudicated criteria. A summary of the covariates used
in the analysis is provided in Table 1.
Exposure-efﬁcacy analysis. The exposure parameters are summarized in Table 2.
The mean calculated exposure at steady state (total area under the concentration-time
curve at steady state [AUCss]) was 101 mg · h/liter, with exposures ranging from 10 to
343 mg · h/liter. Mean trough concentrations at steady state (Css), trough concentra-
tions after 7 days of dosing (C7), and trough concentrations after 14 days of dosing
1 2 3
1
IV or oral 200 mg QD
IV 4 mg/kg or oral 200 mg BID
Follow-up
28 days (±7)
after EOT2 3 42
42
IV 200 mg TID
Isavuconazole
IV 6 mg/kg BID 
Voriconazole
IV 4 mg/kg BID
Study day
Study day
Randomization
1:1
84
84
FIG 1 Study design. BID, twice daily; QD, once daily; TID, three times daily. Maximum therapy duration was 84 days.
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(C14) were approximately 3,600 ng/ml, 2,600 ng/ml, and 3,000 ng/ml, respectively.
Trough concentrations ranged from 174 to 10,000 ng/ml.
All-cause mortality at day 42. All drug exposure parameters (i.e., AUCss, Css, C7,
and C14) were examined graphically and were modeled univariately. There was no
apparent relationship between drug exposure parameters and mortality at day 42
for either the intent-to-treat (ITT) population or the mITT population (Fig. 2A and B,
respectively). None of the primary parameters were retained in the logistic regression
model. Logistic regression analysis did not suggest any positive association between
exposure parameters and mortality at day 42. Since none of the primary exposure
parameters were retained in the model, further covariate analysis was not performed.
DRC-adjudicated overall and clinical responses at end of treatment (EOT).
Graphical examination of binary outcomes for AUCss and Css for the ITT and mITT
populations against clinical and overall responses are shown in Fig. 3A and B, respec-
tively. Logistic regression models did not demonstrate any relationship of drug expo-
sure with mortality, clinical response, and overall response. None of the exposure
parameters were statistically signiﬁcant (at a signiﬁcance level of 0.05) and were not in
the model. Similar results were obtained for C7 and C14 (data not shown).
AUC/MIC calculations. There was only a small sample subset of patients with both
pharmacokinetic (PK) parameters and pathogen susceptibility data available (n  36)
compared with the total number of subjects in the study. Details of patients with MIC
values are provided in Table S1 in the supplemental material. No signiﬁcant relationship
(P 0.05) was identiﬁed between the AUC/MIC ratio and mortality at day 42, the overall
response at EOT, or the clinical response at EOT. Since only 2 of the 36 patients were
not included in the mITT population, the analysis would necessarily have yielded almost
identical results, so it was not performed. No relationship was observed between MIC
values and outcome parameters (13).
Exposure-safety analysis. Patients with PK parameters used in the exposure-
response analysis were also included in this analysis. Graphical examination of binary
outcomes for AUCss and Css for the ITT and mITT populations against normal/elevated
levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are
shown in Fig. 4. None of the primary exposure parameters were found to be statistically
signiﬁcant for any of the safety outcomes (ALT or AST or combined ALT and AST) for
TABLE 1 Summary of patient characteristicsa
Patient characteristic
ITT populationb
(n  231)
mITT population
(n  129)
Yes (n) No (n) Yes (n) No (n)
Hematological malignancy 191 40 100 29
Uncontrolled malignancy 156 75 79 50
Neutropenia 150 81 79 50
Elevated serum galactomannan at baselinec 54 150 51 62
Lower respiratory tract disease 182 49 104 25
aMedian duration of therapy for the ITT population, 51 days, and for the mITT population, 59 days.
bYes/no, had/did not have characteristics at baseline. n is the number of patients.
cThere was no galactomannan information for some patients (n  27) at baseline.
TABLE 2 Summary of exposure parameters
Parameter
Valuea
Mean (SD) Median Range
AUCss (mg · h/liter) 101 (56) 90 10–343
Css (ng/ml) 3,633 (2,023) 3,218 174–10,969
C7 (ng/ml) 2,631 (1,033) 2,477 189–5,627
C14 (ng/ml) 3,049 (1,397) 2,923 174–7,512
aValues are rounded to the nearest whole number. AUCss, total area under the curve at steady state; Css,
concentration at steady state; C7, concentration after 7 days of dosing; C14, concentration after 14 days of
dosing; SD, standard deviation.
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either the ITT (n  226) or mITT (n  126) population. As none of the primary exposure
parameters were signiﬁcant (P  0.3), there was no retention of parameters in the
logistic model.
DISCUSSION
The primary aim of this analysis was to investigate any potential relationship
between various measures of drug exposure of isavuconazole and both efﬁcacy and
safety outcomes. Such an understanding is required to further reﬂect on the potential
requirement for TDM as a component of routine clinical care of patients receiving
isavuconazole. Conducting an exposure-response/safety analysis provides an under-
standing of any threshold of exposure that is predictive of efﬁcacy and/or adverse
events.
We were unable to demonstrate any statistically signiﬁcant relationships for any
measure of drug exposure (i.e., AUCss, Css, or AUC/MIC) and various outcomes (i.e.,
all-cause mortality at day 42 or clinical and overall responses at EOT or MIC of fungal
isolates). A slight trend was observed for overall responses for both the ITT and mITT
populations, but it was not statistically signiﬁcant (P  0.05).
There could be several reasons for the lack of any relationship between drug
exposure and clinical outcomes from this analysis. First, even though there were some
extremes in predicted exposures, the variability was only 62% in the patient population
(12). Second, it is possible there was a degree of bias in the PPK model. The PPK model
was ﬁtted to data from phase 1 and sparse data from phase 3. Even though there were
231 patients in the SECURE study, the sparse data may potentially have led to biased
estimates of exposure and Css values. However, there is no evidence of this, given
concordance with PK models ﬁtted to other isavuconazole data sets (14). Poor com-
pliance with the study drug could also have led to biased estimates of drug exposure,
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FIG 2 Box-and-whisker plots of drug exposure (AUCss and Css) versus mortality at day 42 for the ITT population
(A) and the mITT population (B). Boxes represent the median and 25th and 75th percentiles, whiskers represent the
range of maximum and minimum values within 1.5 the interquartile range, and outliers are shown as circles.
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FIG 3 Box-and-whisker plots of drug exposure (AUCss and Css) versus clinical and overall responses at EOT for the
ITT population (A) and the mITT population (B). Boxes represent the median and 25th and 75th percentiles,
whiskers represent the range of maximum and minimum values within 1.5 the interquartile range, and outliers
are shown as circles.
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FIG 4 Box-and-whisker plots of drug exposure (AUCss and Css) versus ALT/AST levels at EOT for the ITT population
(A) and the mITT population (B). Boxes represent the median and 25th and 75th percentiles, whiskers represent the
range of maximum and minimum values within 1.5 the interquartile range, and outliers are shown as circles.
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although there is no speciﬁc evidence to suggest this occurred. Alternatively, assuming
the existence of a sigmoidal exposure-response relationship, the lack of a relationship
with outcomes might simply reﬂect the fact that exposures were on the plateau of the
curve (suprathreshold). The lack of association between exposure and response is
consistent with the proposition that the isavuconazole exposures achieved by the
clinical dosage regimen were near maximal for treating the infecting organisms in the
SECURE study. In this respect, it is worth noting that the overall cure rate observed for
isavuconazole in the SECURE trial was comparable to those in other trials of triazole
antifungals (2, 5, 15, 16).
Although isolates were not obtained from the majority of patients (and therefore
MIC values for the invading pathogens were not determined), it is likely that most
patients were infected by wild-type organisms. It is possible that the inclusion of more
patients infected with non-wild-type strains might have enabled exposure-response
relationships to be better described. In vivo and ex vivomodels have demonstrated that
the MIC values have a clear impact on exposure-response relationships, as proportion-
ally higher drug exposures are required to achieve the same outcomes for strains with
higher MICs (17–21). Although there were insufﬁcient numbers of patients in the
SECURE study for whom pathogen susceptibility was the only distinction to allow
that possibility to be tested, a few patients with MIC values of up to 8 mg/liter were
successfully treated (5). However, ongoing information from the postlicense database
may eventually enable clinical exposure-response relationships to be better deﬁned.
Even though a threshold value for any drug exposure parameter was not found to
be correlated with mortality and clinical response, the duration of therapy did appear
to be important and was statistically signiﬁcant (P  0.05). This ﬁnding should be
interpreted with some caution. The importance of the duration of therapy may be
confounded by other factors that inﬂuence outcomes (e.g., the nature of the underlying
disease). There is currently no deﬁnitive evidence that suggests that longer duration
of therapy is necessarily associated with a better clinical response. Furthermore, there
is no clear clinical evidence of the minimum duration of antifungal therapy that is
required for clinical cure.
Hepatotoxicity is a class effect for the azole group of antifungal agents, with effects
ranging from mild increase in liver function tests to possibly fatal hepatic failure being
reported (22). The exact mechanism of elevated liver function tests with azole antifun-
gal agents remains unknown (22). Due to the primary concern with elevated liver
function test values, exposure-safety analysis was performed on elevated ALT and AST
levels. These values were available for all the patients. The current analysis did not
identify any association between isavuconazole exposure and elevated ALT or AST
levels or for a combination of both ALT and AST levels. One limitation of this analysis
is the small proportion of patients who had elevated ALT or AST levels. Only 23/226 and
19/226 patients in this analysis had elevated ALT or AST levels, respectively.
Voriconazole, posaconazole, and itraconazole have target trough concentrations
that need to be maintained in order optimize the probability of response. The vori-
conazole target recommended by the British Society of Medical Mycology is between
1.0 and 5.5 mg/liter when the drug is used to treat invasive infection (7). The target
voriconazole concentrations for prophylaxis are less clear. For posaconazole, the target
trough concentrations are 0.7 g/ml for prophylaxis and 1 mg/liter for salvage
therapy. For itraconazole, the target trough concentrations are similar to those for
voriconazole (7). Fluconazole does not require routine therapeutic drug monitoring.
There is no apparent relationship between exposure and efﬁcacy to suggest routine
TDM for isavuconazole. However, it is reasonable to continue observing real-world
patients who are administered isavuconazole and to monitor their exposures when
necessary to ensure they do not require TDM. There might be a necessity to conﬁrm
isavuconazole exposures in select clinical cases (e.g., severe gut disease from graft-
versus-host disease [in which drug absorption through the oral route is problematic], in
treatment of central nervous system infections, or in infections with non-wild-type
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fungal pathogens). TDM may also be necessary when dosing in children or adolescents
due to minimum exposure information (23).
In conclusion, no statistically signiﬁcant relationships were observed for any of the
exposure parameters of isavuconazole (AUCss, Css, C7, and C14) with any safety
markers (ALT, AST, and combined ALT and AST), either at the EOT or postbaseline, or
with any efﬁcacy endpoints (all-cause mortality and overall and clinical responses). In
some models, duration of therapy was retained in the model. However, this covariate
is highly confounded, making its relevance in the analysis unclear. Also, experimental
pharmacodynamic models were conducted to establish the exposure-response rela-
tionship associated with efﬁcacy and to estimate the target exposure associated with
the optimal exposure-response relationship. The results showed that the clinical dosing
regimen achieved exposures adequate to treat infections. All the models were devel-
oped based on the observed data (12); however, the models were not validated against
external data from a clinical trial, which would have required performing additional
isavuconazole studies.
Finally, TDM may be considered for individual cases, as discussed above, but at
present, there is no clear evidence that there is a general need for TDM or a clear target
to recommend.
MATERIALS AND METHODS
Study design. SECURE (ClinicalTrials.gov registration no. NCT00412893) was a global, phase 3,
randomized, multicenter, double-blind, parallel-group noninferiority trial (Fig. 1). Full details of the
SECURE trial have been published previously (5).
Patients with proven/probable disease, as assessed by an independent and blinded DRC, were
included in the mITT population. All the patients received 372 mg of isavuconazonium sulfate (equivalent
to 200 mg isavuconazole) administered by intravenous (i.v.) infusion every 8 h for 6 doses (i.e., days 1 and
2), followed by a maintenance dose of 372 mg isavuconazonium sulfate administered once daily, either
i.v. or orally (p.o.), from day 3 to EOT. Here, only isavuconazole and the dosing equivalent were used.
Efﬁcacy and safety assessments. In the current analysis, the efﬁcacy endpoints included were (i)
all-cause mortality through day 42 in the ITT and mITT populations, (ii) DRC-adjudicated overall response
at EOT in the ITT and mITT populations, and (iii) DRC-adjudicated clinical response at EOT in the ITT and
mITT populations. Liver function test values (AST and ALT) at the EOT and postbaseline (EOT plus 10 days)
were assessed as safety outcomes.
Estimation of pharmacokinetic (exposure) parameters. A PPK model was previously developed
for concentration data from the SECURE study in combination with data from healthy subjects, using
NONMEM version 7.2 (GloboMax LLC, Hanover, MD, USA) (12). This publication lists values and disper-
sions associated with parameters that were used for the simulation. The AUCss was calculated using the
standard formula (AUC  F  dose/CL, where F is bioavailability and CL is clearance) based on the
individual parameter estimates from the best PPK model. Individual parameter estimates obtained from
the best model with covariates were used to calculate Css, C7, and C14.
Exposure-response analysis. All the efﬁcacy and safety data were evaluated as binary and ordinal
data using a logistic regression model in SAS (version 9.3; SAS Institute Inc., Cary, NC, USA). The graphic
processing of the data was also performed in SAS or R (version 2.17; available at https://www.r-project
.org) (24). Each efﬁcacy endpoint and safety endpoint described above was analyzed separately using
isavuconazole exposure parameters.
The covariates were identiﬁed based on scientiﬁc interest or prior knowledge of any possible
relationship with exposure parameters. Duration of therapy was the only continuous covariate investi-
gated. The categorical covariates tested for the exposure-efﬁcacy analysis included race (Caucasian/
Asian), hematological malignancy (yes/no), uncontrolled malignancy at baseline (yes/no), neutropenia at
baseline (yes/no), serum galactomannan at baseline (1/1), and lower respiratory tract disease
(yes/no). Covariates, along with primary exposure parameters, were added in an automated stepwise
approach (  0.3 for model inclusion and   0.05 for model retention).
Exposure-response analyses were also performed for patients in the ITT population who had MIC
values for any Aspergillus spp. (including A. ﬂavus, A. fumigatus, A. niger, and A. terreus). MIC values were
determined by Case Western Reserve University, Cleveland, OH, USA, using the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) methodology (25). AUC0-∞/MIC ratios were calculated
based on model-predicted AUCss values for a patient and the corresponding highest MIC value,
irrespective of the fungus that was cultured.
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